Effect of tamsulosin hydrochloride on lower urinary tract symptoms and quality of life in patients with benign prostatic hyperplasia evaluation using bother score

Drugs of Today

Volumn 43, Issue SUPPL. B, 2007, Pages 1-7

  Yoshida, Masaki ^a   Sugiyama, Yutaka ^a   Masunaga, Koichi ^a   Maeda, Yoshihiro ^a   Satoji, Yo ^a   Nagata, Takashi ^a   Inadome, Akito ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; TAMSULOSIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; EVALUATION; HUMAN; INTERNATIONAL COOPERATION; MAJOR CLINICAL STUDY; NOCTURIA; PROSTATE HYPERTROPHY; QUALITY OF LIFE; SCORING SYSTEM; SYMPTOMATOLOGY; URINARY TRACT DISEASE;

ADMINISTRATION, ORAL; ADRENERGIC ALPHA-ANTAGONISTS; AGED; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SICKNESS IMPACT PROFILE; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME; URINARY TRACT;

EID: 34347243167     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Medina, J.J., Parra, R.O., Moore, R.G. Benign prostatic hyperplasia (the aging prostate). Med Clin North Am 1999, 83: 1213-29.
2. Wolters, R., Wensing, M., van Wheel, C., van der Wilt, G.J., Grol, R.P. Lower urinary tract symptoms: Social influence is more important than symptoms in seeking medical care. BJU Int 2002, 90: 655-61.
3. McVart, K.T. BPH: Epidemiology and comorbidities. Am J Manag Care 206, 12 (Suppl. 5): S122-8.
4. Peters, T.J., Donovan, J.L., Kay, H.E. et al. The International Continence Society "Benign Prostatic Hyperplasia" Study: The bothersomeness of urinary symptoms. J Urol 1997, 157: 885-9.
5. Department of Veterans Affairs. A comparison of quality of life with patient reported symptoms and objective findings in men with benign prostatic hyperplasia. The Department of Veterans Affairs Cooperative Study of transurethral resection for benign prostatic hyperplasia. J Urol 1993, 150: 1696-700.
6. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003, 170: 530-47.
7. Tsujii, T. Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: A short-term open, randomized multicenter study. BPH Medical Therapy Study Group. Benign prostatic hyperplasia. Int J Urol 2000, 7: 199-205.
8. Palacio, A., Hernandez, C., Marques A., Prats J., Espinosa F.J. Long-term study to assess the efficacy of tamsulosin in the control of symptoms and complications developed in patients with symptomatic benign prostatic hyperplasia (OMNICONTROL study): First-year follow-up report. Arch Esp Urol 2004, 57: 451-60.
9. Narayan, P., Evans, C.P., Moon, T. Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol 2003, 170: 498-502.
10. Recommendations of the 2nd International Consensus Committee. In: Cockett, A.T.K., Khoury, S. Aso, Y. et al. (Eds.). Proceedings of the International Consultation on Benign Prostatic Hyperplasia. Scientific Communication International Ltd.: Jersey 1994. 553-672.
11. Ikemoto, I., Kiyota, H., Suzuki, Y. et al. Role of BPH impact index in the evaluation of impaired urination in patients with BPH. Nippon Hinyoukika Gakkai Zasshi 2005, 96: 623-31.
12. Perrin, P., Marionneau, N., Cucherat, M., Taieb, C. Relationship between lower urinary tract symptoms frequency assessed by the IPSS and bothersomeness (SPI) among men older than 50 years old. Eur Urol 2005, 45: 601-7.
13. Andersson, K.E., Chappie, C.R., Hofner, K. Future drugs for the treatment of benign prostatic hyperplasia. World J Urol 2002, 19: 436-42.
14. MacDonagh, R. Quality of life and assessment in urology. Br J Urol 1996, 78: 485-96.
15. th International Consultation of Benign Prostatic Hyperplasia (BPH). SCI: Paris 1998, 265-321.
16. Masumori, N., Kumamoto, Y., Tsukamoto, T., Itoh, N., Tanaka, Y. The effect of subject urinary symptoms on quality of life (QOL) - results of a field survey for prostatic diseases. Nippon Hinyoukika Gakkai Zasshi 1994, 85: 1248-55.
17. Sagnier, P.P., MacFarlane, G., Teillac, P. et al. Impact of symptoms of prostatism on level of bother and quality of life of men in the French community. J Urol 1995, 153: 669-73.
18. Tan, H.Y., Choo, W.C., Archibald, C., Esuvaranathan, K. A community based study of prostatic symptoms in Singapore. J Urol 1977, 157: 890-3.
19. Okajima, E., Ozono, S., Ota, M. et al. A study on international prostate symptom score in the assessment of therapeutic effects and severity of symptoms due to benign prostatic hyperplasia. Nippon Hinyoukika Gakkai Zasshi 1995, 86: 1644-74.
20. Eckhardt, M.D., van Venrooij, G.E., van Melick, H.H., Boon, T.A. Prevalence and bothersomeness of lower urinary tract symptoms in benign prostatic hyperplasia and their inpact on well-being. J Urol 2001, 166: 563-8.
21. Masumori, N., Tanaka, Y., Takahashi, A. et al. Lower urinary tract symptoms of men seeking medical care - comparison of symptoms found in the clinical setting and in a community study. Urology 2003, 62: 266-72.
22. Yoshimura, K., Arai, Y., Ichioka, K. et al. Symptom-specific quality of life in patients with benign prostatic hyperplasia. Int J Urol 2002, 9: 485-90.
23. Van Kerrebroeck, P., Abrams, P., Chaikin, D. et al.; Standardisation Sub-committee of the International Continence Society. The standardisation of terminology in nocturia: Report from the Standardisation Subcommittee of the International Continence Society. Neurourol Urodyn 2002, 21: 179-83.
24. Abram, P. Nocturia: The major problem in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (LUTS/BPO). Eur Urol Suppl 2005, 3: 8-16.
25. Djavan, B., Milani, S., Davies, J., Bolodeoku, J. The impact of tamsulosin oral controlled absorption system (OCAS) on nocturia and the quality of sleep: Preliminary results of a pilot study. Eur Urol Suppl 2005, 4: 61-8.
26. Speakman, M. Efficacy and safety of tamsulosin OCAS. Eur Urol Suppl 2006, 2: 13-7.